Authors : S. S. Wanjari; I. B. Shelke; A. R. Jaiswal

Volume/Issue : Volume 11 - 2026, Issue 3 - March

---

Google Scholar : https://tinyurl.com/4yuwu5ek

Scribd : https://tinyurl.com/4eptassp

DOI : https://doi.org/10.38124/ijisrt/26mar651

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

---

Abstract : Multidrug-resistant tuberculosis (MDR-TB), defined as resistance to Isoniazid and Rifampicin, Poses a major global health threat with treatment success rates around 60-75% using traditional regimens. Recent advances introduce shorter all-oral regimens like BPalm (Bedaquiline,Pretomanid,Linezolid 600mg,Moxifloxacin) for 6 months,achievieng up to 89-93% success in trials suchasTB-PRACTECALandNix-TB, outperforminglonger 18–20-monthoperations.These strategies leveragenew drugs targeting ATP synthases,Mycolic acid, Alongside resistancemechanismslikeGeneticmutationandefflux pumps,Emphasizing Nanotechnology and Host-Directed Approaches,whilehighlightingFutureresearchpriorities.

References :

1. Padmapriyadarsini, C., et al. (2022). Bedaquiline, delamanid, linezolid, and clofazimine for highly drug-resistant pulmonary tuberculosis: an observational study. Clinical Infectious Diseases / PLoS / Lancet regional reporting [PMCID]. (2022).
2. Zumla A, et al. “Drug-resistant tuberculosis—current dilemmas, unanswered questions, challenges, and priority needs.” Lancet Infect Dis.
3. Gandhi NR, et al. “Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Epidemiology and Treatment.” Lancet.
4. Conradie F, et al. “Treatment of Highly Drug-Resistant TB with BPaL Regimen.” N Engl J Med.
5. .Pai, M., Behr, M. A., Dowdy, D., et al. (2016). Tuberculosis. Nature Reviews Disease Primers, 2, 16076.
6. Guirado, E., & Schlesinger, L. S. (2013). Modeling the Mycobacterium tuberculosis granuloma—The critical battlefield in host immunity and disease. Frontiers in Immunology, 4, 98.
7. Zhu, H., et al. (2023). Advances of new drugs bedaquiline and delamanid in tuberculosis treatment. Frontiers / Journal review. 2023
8. Shaw, E. S. (2024). Bedaquiline: what might the future hold? The Lancet Microbe, 2024.
9. Evaluation of the BD MAX™ MDR-TB assay in a real-world setting for the diagnosis of pulmonary and extra-pulmonary TB Original ArticlePublished: 20 February 2020 Volume 39, pages 1321–1327, (2020) of body text
10. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug- Resistant Tuberculosis Giovanni Battista Migliori et al. Int J Mol Sci. 2017.
11. The looming threat of bedaquiline resistance in tuberculosis Eur Respir J. 2020; 55, 2000718.
12. Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management Dale Liebenberg,Bhavna Gowan Gordhan,Bavesh Davandra Kana *2022; 12, 943545
13. Modeling the Mycobacterium tuberculosis Granuloma – the Critical Battlefield in Host Immunity and Disease Evelyn GuirLarry S. Schlesinger *
14. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort S.Koirala et al. Pulmonology. 2021 Sep-Oct.
15. Acquired resistance of Mycobacterium tuberculosis to bedaquiline Koen Andries et al. PLoS One. 2014.